Literature DB >> 8885076

Quinolone-resistant Neisseria gonorrhoeae isolated in Sydney, Australia, 1991 to 1995.

J W Tapsall1, E A Phillips, T R Shultz, C Thacker.   

Abstract

BACKGROUND AND OBJECTIVES: Quinolone antibiotics are used widely for the treatment of gonorrhea, but resistant strains appeared in Sydney in 1984, treatment failure with high-dose regimens in 1991, and isolates with very high minimal inhibitory concentrations (MICs) (16 mg/l) in 1994. GOALS: To examine the frequency, source, and characteristics of Quinolone-resistant Neisseria gonorrhoeae (QRNG) in Sydney from 1991 to 1995 and to compare these data with those obtained from 1984 to 1990. STUDY
DESIGN: The antibiotic sensitivity, auxotype-serovar class, and geographic source of QRNG isolated in Sydney from January 1, 1991 to June 30, 1995 were analyzed.
RESULTS: One hundred seven QRNG were isolated from 97 patients from 1991 to 1995. The number, proportion, and MICs of QRNG increased slowly in the first 4 years of the study and rapidly in the last 6 months. Most QRNG were isolated from travelers entering Sydney from Asia. Twenty-seven different auxotype-serovar classes were detected including 6 auxotype-serovar classes in 14 isolates with high-level quinolone resistance (MIC, 16 mg/l).
CONCLUSIONS: QRNG isolated in Sydney during the past decade originated in Asia as multiple gonococcal subtypes and increased substantially in numbers and levels of resistance in 1995.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885076     DOI: 10.1097/00007435-199609000-00014

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  15 in total

1.  An invasive isolate of Neisseria meningitidis showing decreased susceptibility to quinolones.

Authors:  T R Shultz; J W Tapsall; P A White; P J Newton
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  The antibiotic susceptibility of Neisseria gonorrhoeae isolated in Ulaanbaatar, Mongolia.

Authors:  E Lkhamsuren; T R Shultz; E A Limnios; J W Tapsall
Journal:  Sex Transm Infect       Date:  2001-06       Impact factor: 3.519

3.  Cefaclor, an alternative to third generation cephalosporins for the treatment of gonococcal urethritis in the developing world?

Authors:  F Crabbé; T M Grobbelaar; E van Dyck; Y Dangor; M Laga; R C Ballard
Journal:  Genitourin Med       Date:  1997-12

Review 4.  Epidemiology of gonorrhoea: a global perspective.

Authors:  Robert D Kirkcaldy; Emily Weston; Aluisio C Segurado; Gwenda Hughes
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

5.  Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.

Authors:  T R Shultz; J W Tapsall; P A White
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Molecular basis of high-level ciprofloxacin resistance in Neisseria gonorrhoeae strains isolated in Denmark from 1995 to 1998.

Authors:  X Su; I Lind
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Surveillance of antibiotic susceptibility of Neisseria gonorrhoeae in the WHO western Pacific region 1992-4. WHO Western Pacific Region Gonococcal Antimicrobial Surveillance Programme.

Authors: 
Journal:  Genitourin Med       Date:  1997-10

8.  Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure.

Authors:  C A Ison; P J Woodford; H Madders; E Claydon
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 9.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

10.  Antimicrobial susceptibility of Neisseria gonorrhoeae strains isolated in Guangzhou, China, 1996-2001.

Authors:  H P Zheng; W L Cao; X Z Wu; L G Yang
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.